CytomX reports Phase I data for CX-072 in solid tumors

CytomX Therapeutics Inc. (NASDAQ:CTMX) reported preliminary data from the Phase I/II PROCLAIM-072 trial evaluating CX-072 as monotherapy and in combination with anti-CTLA-4 mAb Yervoy ipilimumab or BRAF inhibitor Zelboraf vemurafenib to treat metastatic or locally advanced unresectable solid tumors or lymphomas. The data were released in a pair of abstracts ahead of the American Society of Clinical Oncology (ASCO) meeting in Chicago. CX-072 is a Probody targeting PD-L1.

In 17 evaluable patients with heavily pretreated solid tumors, IV CX-072 every 14 days as monotherapy led to partial responses in one patient with thymoma and one PD-L1-negative triple-negative breast cancer (TNBC) patient, plus 11 cases of stable disease...